- WKN: A2TSL7
- ISIN: DE000A2TSL71
- Land: Deutschland
Nachricht vom 29.07.2021 | 10:01
SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer
DGAP-News: SYNLAB AG
/ Key word(s): Alliance
SYNLAB, Europe's leading medical diagnostic services provider, and AXA Partners enter a partnership to facilitate safe and easy travelling for customers and employees. AXA Partners is part of the AXA Group, a global leader in insurance and asset management, with more than 9,000 employees serving customers worldwide.
Leveraging SYNLAB's broad laboratory network, AXA Partners' customers and employees are being offered comprehensive COVID-19 testing services in more than 10 European countries, including Spain, Portugal and France and covering around 900 testing centres. The partnership may be extended to include further countries.
PCR tests are considered gold standard for COVID-19 testing, providing the highest possible sensitivity and specificity. A negative PCR test result ensures that customers and employees are not infected with SARS-CoV-2, which helps to protect their environment. In addition, it can also facilitate their on-/homeward journey and border crossing. Besides PCR testing, the partnership also includes antigen tests and self-administrated test kits, if country regulation permits.
AXA Partners' customers and employees can find SYNLAB laboratories and sample collection points through AXA Partners' vetted medical network, whereby SYNLAB - as the preferred partner in testing for COVID-19 - is ranked first on search results.
Mathieu Floreani, CEO of SYNLAB, says: "At a time when people around the world want to resume travel and different variants of the SARS-CoV-2 virus are spreading, testing remains crucial. We are pleased that AXA Partners has chosen SYNLAB as the preferred provider for testing. Together, we will make travel as safe as possible for their customers and employees."
Julia d'Astorg, Chief International Medical Services Officer, AXA Partners: "We at AXA Partners continually strive to provide a best-in-class health services to our customers. This means that when looking for a Partner, we always ensure that their standard of service, ethos and ability to promptly innovate are aligned with ours. We are very happy to have found that in SYNLAB."
For more information:
|Moosacher Straße 88|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1222522|
|End of News||DGAP News Service|
SYNLAB delivers strong 9M 2021 results, on tra ...
SYNLAB closes the acquisition of 100 percent o ...
SYNLAB announces upward revision of FY'21 guidance
SYNLAB expands partnership with Feedtrail to g ...
SYNLAB delivers outstanding financial and oper ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 16:48 Update DocuSign: Minus steigt auf 40 Prozent! Der nächste ...
03. Dezember 17:00 DAX: Der nächste Nackenschlag
03. Dezember 17:54 Börsenpunk: DAX - Angst ist zurück an den Märkten - jetzt trotzdem ...
03. Dezember 18:09 Alibaba, Tencent und Co: Kleiner Crash vorm Wochenende
03. Dezember 18:19 Musterdepot-Titel BHP: Es geht voran
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021